Literature DB >> 2060186

Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization.

S P Leong1, M E Granberry, Y M Zhou, T F Wang, T M Grogan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2060186     DOI： 10.1007/bf01753732

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN： 0262-0898            Impact factor:   5.150


× No keyword cloud information.
  15 in total

1.  Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.

Authors:  T M Grogan; B G Durie; C Lomen; C Spier; D P Wirt; R Nagle; G S Wilson; L Richter; E Vela; V Maxey
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

Review 2.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

Authors:  G Parmiani; A Anichini; G Fossati
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

3.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

Authors:  C M Balch; L B Riley; Y J Bae; M A Salmeron; C D Platsoucas; A von Eschenbach; K Itoh
Journal:  Arch Surg       Date:  1990-02

4.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

5.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Authors:  L M Muul; P J Spiess; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Authors:  A Knuth; B Danowski; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2.

Authors:  P Hersey; C Bindon; A Edwards; E Murray; G Phillips; W H McCarthy
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

9.  Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression.

Authors:  B Mukherji; A L Nashed; A Guha; M T Ergin
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

10.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728
View more
  1 in total

1.  Generation of cytotoxic effector cells against human melanoma.

Authors:  S P Leong; Y M Zhou; M E Granberry; T F Wang; T M Grogan; C Spier; R White; A Mehta; A Y Lin
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.